Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model.
about
Advances of molecular subtype and targeted therapy of lung cancerMutant HRAS as novel target for MEK and mTOR inhibitorsFeasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer.A Phase I Trial of Temsirolimus and Pemetrexed in Patients with Advanced Non-Small Cell Lung Cancer.Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung CancerTargeted therapies in non-small cell lung carcinoma: what have we achieved so far?Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma.Advances towards the design and development of personalized non-small-cell lung cancer drug therapy.The Biological Role of PI3K Pathway in Lung Cancer.Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatmentTumour growth of colorectal rat liver metastases is inhibited by hepatic arterial infusion of the mTOR-inhibitor temsirolimus after portal branch ligation.Regulators of Glucose Metabolism in CD4(+) and CD8(+) T Cells.Dose-finding designs for trials of molecularly targeted agents and immunotherapies.
P2860
Q27030813-9B4A2F22-5DEB-4EFE-A2BA-0F3305C99318Q27853238-C7D6103B-0E2D-4117-B7DB-FA12FED59819Q33407021-4B1480C1-D3F0-4640-81EA-49A1441652EDQ33429306-39C52DED-3262-44A2-A759-7911B1B38FE3Q33572258-D5C7F509-7CF1-4173-836F-7C64FF18D838Q35463464-0D8E8216-4CFC-4075-8DB0-39EDB9E49738Q36999705-6DBC2528-E18C-458C-8690-B22378143766Q37373041-332BE616-AFC3-4D3E-9FFC-942FA2936B6AQ38148583-50C18584-D328-4FFB-8299-48BC60EF9AAFQ38166599-FF18C2E4-691F-474A-A460-163855F8A7B3Q38262500-35F068EE-3DDF-40E1-AA50-8C177DCDDEDFQ38908325-4554C4BD-35AC-4815-9CBB-6AE564480AA1Q40895626-C3937DF7-F330-466B-9B25-443694316531Q53522981-B47D50A5-A98E-4A6D-8BC7-5BA03916173D
P2860
Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Everolimus in combination with ...... ayesian dose-escalation model.
@ast
Everolimus in combination with ...... ayesian dose-escalation model.
@en
type
label
Everolimus in combination with ...... ayesian dose-escalation model.
@ast
Everolimus in combination with ...... ayesian dose-escalation model.
@en
prefLabel
Everolimus in combination with ...... ayesian dose-escalation model.
@ast
Everolimus in combination with ...... ayesian dose-escalation model.
@en
P2093
P1476
Everolimus in combination with ...... ayesian dose-escalation model.
@en
P2093
Beatrijs Anrys
Benjamin Solomon
Eckart Laack
Ilona Pylvaenaeinen
Johan Vansteenkiste
Jürgen Wolf
Katarina Petrovic
Lilla Di Scala
Neil Miller
Sasa Dimitrijevic
P304
P356
10.1097/JTO.0B013E3182307EDE
P50
P577
2011-12-01T00:00:00Z